BACKGROUND BRIEFING: Made in Australia - COVID-19 vaccine manufacturing explained

Embargoed until: Publicly released: 2021-02-12 11:12

Australia; VIC

Image by hakan german from Pixabay

As the Australian Government prepares to roll out the COVID-19 vaccination program, CSL has been busily manufacturing the AstraZeneca COVID-19 vaccine (recombinant adenovirus vaccine). CSL has a contract to manufacture 50 million doses of the AstraZeneca vaccine for use by Australians and is on track to deliver the first doses - tested, approved and released by the TGA (subject to TGA approval) – from late March. Representatives from CSL and Seqirus’ advanced manufacturing facilities in Broadmeadows and Parkville, Victoria will explain the process of manufacturing the AstraZeneca vaccine – starting from the first ‘vial thaw’ through to ‘harvest’ of the product in bulk, to formulation and ‘fill and finish’ into dose vials.

Media release

From:

Speakers:

Dr Anthony Stowers, Senior Vice President, Recombinant Product Development, CSL
Mr Chris Larkins, Senior Vice President, Manufacturing Operations, Seqirus
Dr Andrew Nash, Chief Scientific Officer, CSL (no presentation)

Declaration: CSL is a supporter of the Australian Science Media Centre and contributes ~1% of the Centre's budget. See all our supporters and read about our independence.

Attachments

Note: Not all attachments are visible to the general public. Research URLs will go live after the embargo ends.

Video Australian Science Media Centre, Web page Full recording of the briefing

Journal/
conference:

Organisation/s: CSL Innovation Pty Ltd

Funder: CSL is a supporter of the Australian Science Media Centre and contributes ~1% of the Centre's budget. See all our supporters and read about our independence.

Media Contact/s

Contact details are only visible to registered journalists.